SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Abstract creative financial graph with finger clicks on a digital tablet on background, forex and investment concept.
Legal
Investment Banker Accused of Leaking Pharma M&A Secrets in $41M Insider Trading Scheme
The banker allegedly shared details of a series of multibillion-dollar buyouts by companies including AbbVie, GSK and Pfizer.
December 23, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Brussels, Belgium. 21st December 2020. Exterior view of Pfizer Pharmaceutical company's offices.
Clinical research
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A
The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.
December 23, 2025
 · 
1 min read
 · 
Annalee Armstrong
Made in USA, with USA Map. 3D Illustration
Manufacturing
2025: The Year Trump Pushed Manufacturing Into the Spotlight
A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.
December 23, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Banner collage poster online news fake info journalism reportage arm hold newspaper isolated on creative drawing background.
Business
ICYMI: 5 BioSpace Features From 2025 That Stand the Test of Time
Of all the stories we published this year, these deep dives by BioSpace editors stand out as relevant re-reads going into the New Year.
December 23, 2025
 · 
6 min read
 · 
Jef Akst
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Drug pricing
Trump Administration Reaches Pricing Agreements With 9 More Drugmakers
Leerink analysts hailed the deals as a sign that President Trump “is unlikely to attack the industry in 2026.”
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Policy
Disc Shares Slip Amid Report FDA’s Prasad Is Skeptical of Bitopertin’s Efficacy
The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Hand holding a lung shape symbol against a blue background. World tuberculosis day, world no tobacco day, lung cancer, pulmonary hypertension, pneumonia
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
December 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.
December 22, 2025
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS